Efficacy of hemopoietic-stimulating factors in patients undergoing chronic hemodialysis

Autor:	Vasileios Kolovos, Giorgos Ntatsis, Aristeidis Sgantzos, Nikolaos Kaperonis, Antonios Zagorianakos, Stavroula Ziakka, Dimitrios Poulikakos, Nicolas Papagalanis, Alexandra Koutsovasili
Rok vydání:	2011
Předmět:	Adult Male medicine.medical_specialty Dose Anemia medicine.medical_treatment Critical Care and Intensive Care Medicine Hemoglobins Renal Dialysis Internal medicine medicine Humans In patient Chronic hemodialysis Renal Insufficiency Intensive care medicine Aged business.industry General Medicine Middle Aged medicine.disease Haematopoiesis Target level Nephrology Hematinics Female Hemodialysis Hemoglobin business
Zdroj:	Renal failure. 33(10)
ISSN:	1525-6049
Popis:	Anemia has been linked to increased mortality and morbidity in renal hemodialysis patients. Other risk factors that contribute to an adverse outcome include the variability of hemoglobin (Hb) levels and the decreased response to erythropoiesis-stimulating factors (ESFs). In this study we evaluated the effectiveness of four different ESFs (epoetin-A, epoetin-B, darbepoetin, and CERA), assessed the variability of Hb levels, and compared ESF dosages which contributed to the achievement of Hb levels in each individual patient with renal failure undergoing chronic hemodialysis maintenance. In conclusion, the four ESFs administered are equally effective in the treatment of anemia in renal hemodialysis patients and they do not influence in a different manner the variability of Hb. The administration of darbepoetin-A and CERA might possibly cause more patients to overshoot the target level of Hb.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b328e880ef87860cefbdce93c5abb6 https://pubmed.ncbi.nlm.nih.gov/22013927 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.